Frankfurt - Delayed Quote ? EUR XBiotech Inc. (4XB.F) Follow Compare 6.55 +0.05 (+0.77%) At close: October 25 at 8:09 AM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations XBiotech: Q2 Earnings Snapshot AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Monday reported a loss of $13 million in its second quarter. The Austin, Texas-based company said it had a loss of 43 cents per share. Associated Press Finance ? 2 months ago XBIT XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen GlobeNewswire ? 4 months ago XBIT XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by... Simply Wall St. ? 7 months ago XBIT XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou GlobeNewswire ? 9 months ago XBIT Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... Simply Wall St. ? 10 months ago XBIT Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis (Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for rheumatological diseases. The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Con GlobeNewswire ? 11 months ago XBIT Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 4XB.F S&P 500 YTD +85.03% +21.77% 1-Year +79.95% +36.74% 3-Year -44.16% +27.79%
